Open-Label Extension Trial Supports Long-Term Use of Viloxazine ER in Children and Adolescents 

 ADHD in the News 2026-04-23


Viloxazine ER (viloxazine extended-release capsules) is a selective norepinephrine transporter inhibitor and non-stimulant that is FDA-approved for the treatment of pediatric (≥6 years of age) and adult ADHD.1 A phase 3 open-label extension (OLE) trial evaluated the long-term safety (primary endpoint) and efficacy (secondary endpoint) of viloxazine ER for children (aged 6-11 years) and adolescents (aged 12-18 years) with ADHD.2  

View Article: Psych Congress Network, April 13, 2026




Other Articles in this Edition

Lawmaker presses RFK Jr. on comments on ‘re-parenting’ Black kids 

Inspirational success stories are great but is ADHD really a superpower for elite athletes? 

Influencers Are Spinning Nicotine as a ‘Natural’ Health Hack

ADHD and chronic pain, an overlooked connection 

He maps brains of children and teens with ADHD 

Let’s Ask Brains What ADHD Looks Like 

ADHD in women: Breaking the stereotypes 

Researchers identify ADHD and social traits in preschoolers with heart defects

Parents of Kids With Neurodevelopmental Disorders May Face Greater Heart Risk

6 Ways ADHD Can Hide Autism 

Children with ADHD report applying less effort on cognitive tasks compared to their peers

Mental health during the pandemic in children and young people with mental health and neurodevelopmental conditions

Open-Label Extension Trial Supports Long-Term Use of Viloxazine ER in Children and Adolescents 

Vaping may raise cognitive impairment risk in young adults, study finds

ADHD treatment despite a history of psychosis: Research finds no increased risk of relapse